8-K: Candel Therapeutics Announces Positive Interim Phase 2 Data for CAN-2409 in Pancreatic Cancer

Candel Therapeutics reports significantly improved survival rates in patients with pancreatic cancer treated with CAN-2409 in a Phase 2 clinical trial.

Summary

• Candel Therapeutics announced positive interim results from its Phase 2 clinical trial of CAN-2409 in patients with non-metastatic pancreatic cancer.
• The study showed a median overall survival of 28.8 months in the CAN-2409 group compared to 12.5 months in the control group.
• At 24 months, the survival rate was 71.4% in the CAN-2409 group versus 16.7% in the control group.
• At 36 months, the estimated survival rate was 47.6% in the CAN-2409 group compared to 16.7% in the control group.
• The treatment also demonstrated a favorable safety profile with no dose-limiting toxicities or cases of pancreatitis.
• Analysis of tumor samples showed an increase in immune cells, indicating a robust anti-tumor immune response.

Sentiment

Score: 9

Explanation: The document presents very positive interim results from a Phase 2 clinical trial, showing significant improvements in survival rates and a favorable safety profile. This is a major positive development for the company and its treatment.

Positives

• The CAN-2409 treatment significantly improved median overall survival compared to the control group.
• The survival rates at 24 and 36 months were substantially higher in the CAN-2409 group.
• The treatment demonstrated a favorable safety profile with no significant adverse events.
• The study showed evidence of a robust anti-tumor immune response in treated patients.
• The results suggest that CAN-2409 can convert progressive cancer into a chronic disease associated with improved survival.

Risks

• The study is an interim analysis, and final data may differ from the reported results.
• The clinical trial is not currently enrolling new patients.
• The company's ability to continue as a going concern is a risk factor.
• There are risks associated with the timing and advancement of development programs.

Future Outlook

The company is focused on advancing its clinical programs and expects to provide further updates as data becomes available. They are also working on other clinical trials for different cancers.

Management Comments

• Garrett Nichols, MD, MS, Chief Medical Officer of Candel, stated that effective new treatment options are urgently needed for non-metastatic PDAC.
• Garrett Nichols also said they are very encouraged by the improved survival associated with CAN-2409.
• Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel, noted that the immunological changes induced by CAN-2409 suggest it can change the balance between the tumor and the patient's anti-tumor immune response.

Industry Context

The announcement is significant as pancreatic cancer has a poor prognosis and limited treatment options. The positive results from Candel's trial could represent a major advancement in the treatment of this disease. The failure of conventional immunotherapy in pancreatic cancer makes this result even more important.

Comparison to Industry Standards

• The median overall survival of 28.8 months in the CAN-2409 group is significantly higher than the 22.2 months reported in a recent meta-analysis of neoadjuvant FOLFIRINOX with or without radiotherapy for borderline resectable PDAC.
• The 24-month survival rate of 71.4% in the CAN-2409 group is substantially better than the 16.7% in the control group, and also better than the historical survival rates for this disease.
• The results are also notable when compared to the limited success of PD-1 and CTLA-4 antibodies in pancreatic cancer, which have been largely unsuccessful due to the tumor's microenvironment.

Stakeholder Impact

• Shareholders will likely react positively to the significant improvement in survival rates.
• Patients with pancreatic cancer may have a new treatment option with improved outcomes.
• Employees of Candel Therapeutics may be motivated by the positive results.
• The results may attract potential partners and investors.

Next Steps

• The company will continue to monitor the patients in the clinical trial.
• Candel will continue to advance its clinical programs for CAN-2409 in other cancers.
• The company will likely seek regulatory approval based on the positive results.

Key Dates

Keywords

CAN-2409, pancreatic cancer, immunotherapy, clinical trial, survival rate, tumor microenvironment, adenovirus, PDAC, immune response, biopharmaceutical